163 related articles for article (PubMed ID: 20093378)
1. In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa.
Tomozawa T; Sugihara C; Kakuta M; Sugihara K; Koga T
J Med Microbiol; 2010 Apr; 59(Pt 4):438-441. PubMed ID: 20093378
[TBL] [Abstract][Full Text] [Related]
2. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Koga T; Masuda N; Kakuta M; Namba E; Sugihara C; Fukuoka T
Antimicrob Agents Chemother; 2008 Aug; 52(8):2849-54. PubMed ID: 18519723
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
Sugihara K; Sugihara C; Matsushita Y; Yamamura N; Uemori M; Tokumitsu A; Inoue H; Kakuta M; Namba E; Nasu H; Koga T
Antimicrob Agents Chemother; 2010 Dec; 54(12):5298-302. PubMed ID: 20921311
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection.
Sugihara K; Tateda K; Yamamura N; Koga T; Sugihara C; Yamaguchi K
Antimicrob Agents Chemother; 2011 Nov; 55(11):5004-9. PubMed ID: 21844314
[TBL] [Abstract][Full Text] [Related]
5. The postantibiotic effect of meropenem and imipenem on selected bacteria.
Nadler HL; Pitkin DH; Sheikh W
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():225-31. PubMed ID: 2509416
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
MacGowan AP; Bowker KE; Noel AR
Antimicrob Agents Chemother; 2008 Apr; 52(4):1401-6. PubMed ID: 18227179
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
8. In vitro postantibiotic effect of imipenem and enoxacin alone and in combination against Pseudomonas aeruginosa.
Hostacká A
Pharmazie; 1997 Jul; 52(7):544-6. PubMed ID: 9266592
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Nagano R; Shibata K; Adachi Y; Imamura H; Hashizume T; Morishima H
Antimicrob Agents Chemother; 2000 Mar; 44(3):489-95. PubMed ID: 10681308
[TBL] [Abstract][Full Text] [Related]
10. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
Mizunaga S; Kamiyama T; Fukuda Y; Takahata M; Mitsuyama J
J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
[TBL] [Abstract][Full Text] [Related]
14. The antibacterial activity of meropenem in combination with gentamicin or vancomycin.
Wise R; Ashby JP; Andrews JM
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():233-8. PubMed ID: 2509417
[TBL] [Abstract][Full Text] [Related]
15. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2005)].
Goto H; Takeda H; Kawai S; Watanabe S; Okazaki M; Shimada K; Nakano K; Yokouchi H; Mori T; Igari J; Oguri T; Yamamoto M; Kudo K; Kobayashi N; Tanaka T; Yoshimura K; Kawabata M; Nakamori Y; Sumitomo M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Aoki N; Honma Y; Suzuki Y; Karasawa Y; Oka M; Kobashi Y; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Oikawa S
Jpn J Antibiot; 2008 Aug; 61(4):209-40. PubMed ID: 19024644
[TBL] [Abstract][Full Text] [Related]
16. Mutant selection window of disinfectants for Staphylococcus aureus and Pseudomonas aeruginosa.
Kawamura M; Fujimura S; Tokuda K; Aoyagi T; Endo S; Kanamori H; Watanabe A; Kaku M
J Glob Antimicrob Resist; 2019 Jun; 17():316-320. PubMed ID: 30684653
[TBL] [Abstract][Full Text] [Related]
17. Bacterial brothers in arms: cooperation of Staphylococcus aureus and Pseudomonas aeruginosa during antimicrobial exposure.
Lenhard JR; Smith NM; Quach CD; Nguyen TQ; Doan LH; Chau J
J Antimicrob Chemother; 2019 Sep; 74(9):2657-2665. PubMed ID: 31219553
[TBL] [Abstract][Full Text] [Related]
18. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
19. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
[TBL] [Abstract][Full Text] [Related]
20. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.
Hawser SP; Bouchillon SK; Hoban DJ; Dowzicky M; Babinchak T
Int J Antimicrob Agents; 2011 Mar; 37(3):219-24. PubMed ID: 21239146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
